Helix BioPharma Corp., of Richmond Hill, Ontario, said that following board approval it is exploring a partnership, alliance, joint development or licensing transaction of its L-DOS47 drug product candidate currently in clinical trials for the treatment of nonsquamous small-cell lung cancer.